AT-108

AT-108 is a first-in-class, off-the-shelf gene therapy developed for cancer immunotherapy. It utilizes a replication-deficient adenoviral vector to deliver three proprietary reprogramming factors directly into tumor cells. This process reprograms the tumor cells in vivo to become conventional type 1 dendritic cells (cDC1s), which are critical for mounting efficient cytotoxic T cell responses and effective anti-tumor immunity. By converting tumor cells into antigen-presenting cDC1-like cells, AT-108 enhances antigen presentation, overcomes immune evasion, and induces personalized and systemic anti-cancer immune responses—even in tumors resistant to checkpoint inhibitors or with non-immunogenic microenvironments. Preclinical studies have demonstrated durable tumor regression, long-term systemic memory, and protection against metastatic challenge[3][5][6][7][9][10].